ClinicalTrials.gg
Active, not recruitingNCT06730750Updated Sep 1, 2026

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

A Phase 1/2 interventional study of BMS-986490 and Bevacizumab in Advanced Solid Tumors, sponsored by Bristol-Myers Squibb. Active, not recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.

Planned enrollment
8th of 27
360 · median 171
Started
2025
with 3 others
Phase 1/2
10 of 29
2 open now
Registered
25th of 29
by date

Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 in phase 1/2, and was the 25th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Colorectal Cancer (CRC)
  • Non-small Cell Lung cancer (NSCLC)
  • Gastric Cancer (GC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented or cytologically confirmed, advanced, unresectable/ solid tumor measurable by v1.1.
  • CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:

    i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not ).

  • NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC:

    i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.

ii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.

- GC: Part 2A-NSCLC/GC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).

ii) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylactic reactions to irinotecan and/or bevacizumab.
  • Previously received therapy targeting CEACAM5.
  • Grade ≥3 ILD/pneumonitis.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Part 1A

    Drug: BMS-986490

  • Experimental
    Part 2A - Colorectal Cancer (CRC)

    Drug: BMS-986490

  • Experimental
    Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC)

    Drug: BMS-986490

  • Experimental
    Part 1B

    Drug: BMS-986490 · Drug: Bevacizumab

  • Experimental
    Part 2B

    Drug: BMS-986490 · Drug: Bevacizumab

Interventions

  • DrugBMS-986490

    Specified dose on specified days.

  • Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Number of participnats with Adverse Events (AEs)

    Time frame: Up to 100 days following discontinuation of dosing

  2. Number of participants with Serious AEs (SAEs)

    Time frame: Up to 100 days following discontinuation of dosing

  3. Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria

    Time frame: Up to 28 days after the first treatment of study intervention

  4. Number of participants with AEs leading to discontinuation

    Time frame: Up to 100 days following discontinuation of dosing

  5. Number of deaths

    Time frame: Up to 100 days following discontinuation of dosing

Secondary outcomes

  1. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)

  2. Trough observed concentration (Ctrough)

    Time frame: Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)

  3. Maximum observed concentration (Cmax)

    Time frame: Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)

  4. Time of maximum observed concentration (Tmax)

    Time frame: Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)

  5. Total anti-drug antibodies (ADAs)

    Time frame: Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)

  6. Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by Investigator

    Time frame: Up to approximately 4 years

07

Study locations

6 sites
  • Local Institution - 0007
    Los Angeles, California 90033, United States
  • Local Institution - 0017
    Grand Rapids, Michigan 49546, United States
  • Local Institution - 0004
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0006
    Pittsburgh, Pennsylvania 15232, United States
  • Tasman Oncology Research
    Southport, Queensland 4215, Australia
  • Local Institution - 0003
    Toronto, Ontario M5G 2M9, Canada
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 18 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Feb 12, 2025
Primary completionEst.
Sep 5, 2026
CompletionEst.
Dec 9, 2029
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06730750
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Feb 12, 2025
Primary completion
Sep 5, 2026 (estimated)
Completion
Dec 9, 2029 (estimated)
Last update
Sep 1, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion